SK88793A3 - Amylin agonising peptides and their using - Google Patents

Amylin agonising peptides and their using Download PDF

Info

Publication number
SK88793A3
SK88793A3 SK887-93A SK88793A SK88793A3 SK 88793 A3 SK88793 A3 SK 88793A3 SK 88793 A SK88793 A SK 88793A SK 88793 A3 SK88793 A3 SK 88793A3
Authority
SK
Slovakia
Prior art keywords
amylin
pro
ser
lys
leu
Prior art date
Application number
SK887-93A
Other languages
English (en)
Slovak (sk)
Inventor
Laura S L Gaeta
Howard Jones
Elisabeth Albrecht
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SK88793A3 publication Critical patent/SK88793A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK887-93A 1991-11-19 1992-11-19 Amylin agonising peptides and their using SK88793A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79426691A 1991-11-19 1991-11-19
PCT/US1992/009842 WO1993010146A1 (en) 1991-11-19 1992-11-19 Amylin agonist peptides and uses therefor

Publications (1)

Publication Number Publication Date
SK88793A3 true SK88793A3 (en) 1994-12-07

Family

ID=25162163

Family Applications (1)

Application Number Title Priority Date Filing Date
SK887-93A SK88793A3 (en) 1991-11-19 1992-11-19 Amylin agonising peptides and their using

Country Status (17)

Country Link
EP (2) EP0567626B1 (ja)
JP (4) JP2902115B2 (ja)
AT (1) ATE205854T1 (ja)
AU (1) AU714439B2 (ja)
CA (1) CA2100745C (ja)
CZ (1) CZ288029B6 (ja)
DE (1) DE69232064T2 (ja)
DK (1) DK0567626T3 (ja)
ES (1) ES2161697T3 (ja)
FI (1) FI118601B (ja)
GR (1) GR3036794T3 (ja)
HK (1) HK1041891A1 (ja)
MD (1) MD960317A (ja)
NO (2) NO324405B1 (ja)
RU (1) RU2130463C1 (ja)
SK (1) SK88793A3 (ja)
WO (1) WO1993010146A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
KR100429966B1 (ko) * 1993-09-07 2004-05-04 아밀린 파마슈티칼스, 인크. 위장 운동성 조절을 위한 제약 조성물
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
EP1044015B1 (en) * 1998-01-09 2008-10-08 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides with insulin
GB0128583D0 (en) 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
US8168233B2 (en) 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
CA2516726A1 (en) * 2003-03-18 2004-09-30 Applied Research Systems Ars Holding N.V. Amylin aggregation inhibitors and use thereof
KR20070083815A (ko) * 2004-10-26 2007-08-24 론자 아게 고체상 합성에서 ｓ-알킬-술페닐 보호기
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
ES2330671T3 (es) 2005-03-31 2009-12-14 Amylin Pharmaceuticals, Inc. Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos.
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
NZ595021A (en) 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EA201690938A1 (ru) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
DK3137494T3 (da) * 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
KR102130354B1 (ko) * 2019-08-14 2020-07-06 엘아이지넥스원 주식회사 코어 제거용 이형장치
EP4319798A1 (en) 2022-05-30 2024-02-14 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
EP0348490B1 (en) * 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
NZ234428A (en) * 1989-07-10 1997-08-22 Amylin Corp Use of an amylin antagonist in the treatment of obesity and essential hypertension
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues

Also Published As

Publication number Publication date
CZ288029B6 (cs) 2001-04-11
NO20073265L (no) 1993-09-17
JP2003238594A (ja) 2003-08-27
DE69232064T2 (de) 2002-03-28
AU714439B2 (en) 2000-01-06
ES2161697T3 (es) 2001-12-16
FI118601B (fi) 2008-01-15
CZ168993A3 (en) 1994-04-13
FI933252A0 (fi) 1993-07-16
RU2130463C1 (ru) 1999-05-20
HK1041891A1 (zh) 2002-07-26
AU1245697A (en) 1997-03-27
CA2100745C (en) 2007-07-31
EP1162207A1 (en) 2001-12-12
GR3036794T3 (en) 2002-01-31
NO324405B1 (no) 2007-10-08
JPH06504794A (ja) 1994-06-02
CA2100745A1 (en) 1993-05-20
FI933252A (fi) 1993-08-23
JP4018116B2 (ja) 2007-12-05
MD960317A (ro) 1998-05-31
NO932603L (no) 1993-09-17
WO1993010146A1 (en) 1993-05-27
AU673147B2 (en) 1996-10-31
EP0567626A1 (en) 1993-11-03
JP2006213716A (ja) 2006-08-17
JP2902115B2 (ja) 1999-06-07
ATE205854T1 (de) 2001-10-15
NO932603D0 (no) 1993-07-19
JPH11152299A (ja) 1999-06-08
EP0567626B1 (en) 2001-09-19
DE69232064D1 (de) 2001-10-25
DK0567626T3 (da) 2001-12-17
AU3075392A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
SK88793A3 (en) Amylin agonising peptides and their using
US7271238B2 (en) Amylin agonist peptides and uses therefor
AU2017216533B2 (en) Improved peptide pharmaceuticals
AU766545B2 (en) Novel anti-diabetic peptides
CA2891929C (en) Improved peptide pharmaceuticals
JP2022172128A (ja) インスリン抵抗性のための改善されたペプチド医薬品
CN103732617A (zh) 用于胰岛素抵抗的改进的肽医药
JP2003501361A (ja) 妊娠糖尿病の治療のためのエキセンジンおよびそのアゴニストの使用
JP2003522721A (ja) 新規なエキセンジンアゴニスト化合物
JP2001513512A (ja) 新規なエキセンディン作動剤化合物
SK88893A3 (en) Novel amylin antagonist peptides and uses therefor
EA038073B1 (ru) Ацилированное инсулиновое соединение
JP2002522355A (ja) 新規な混合アミリン活性化合物
AU669636B2 (en) Amylin antagonists and agonists
AU673147C (en) Amylin agonist peptides and uses therefor
KR20230106481A (ko) 지속형 지방산-펩타이드 유도체 및 이의 용도